AIMT News and Press, Aimmune Therapeutics Inc. From 10/08/19

According to industry and sector data analysed by GlobalData, Merck's ( MRK ) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myer...

The major point for this article is to discuss the conflicting information that MannKind has issued in recent public events, information that is in direct conflict with information shared on every Afrezza prescription that is filled for a patient. The nature of this conflict is critical inform...

Shares of Aimmune Therapeutics (NASDAQ: AIMT) , a company developing a peanut desensitization therapy, jumped 12% on Wednesday after an analyst shared the results of an informal survey. It looks like the company's lead candidate, Palforzia, could exceed expectations if the Food and Drug Admi...

Gainers : The Stars Group (NASDAQ: TSG ) +29% . Naked Brand Group (NASDAQ: NAKD ) +15% . Yuma Energy (NYSEMKT: YUMA ) +15% . Surface Oncology (NASDAQ: SURF ) +14% . Catalyst Biosciences (NASDAQ: CBIO ) +13% . NIO (NYSE: NIO ) +13% . Zynex (NASDAQ: ZYXI ) +11% . Aimmune Therapeutics ...

Gainers:  VHC   +20.9% . AIMT   +9.9% . AOBC   +2.8% . RDFN   +5.1%.  DRNA   +4.1% . More news on: VirnetX Holding Corp, Aimmune Therapeutics, Inc., American Outdoor Brands Corporation, Stocks on the move, , News on ETFs Read more ...

Piper Jaffray says a new proprietary allergist survey shows "massive upside" to sales potential and expectations for Aimmune's (NASDAQ: AIMT ) peanut allergy drug. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Cantor Global Healthcare Conference on Thursday, October 3...

Aimmune Therapeutics ( AIMT ) recently had an advisory panel convene to determine if its peanut allergy treatment Palforzia (AR101) should be recommended for approval. The final vote in terms of recommending possible approval of the drug was highly positive. The panel did back the safety o...

A wave of vaping-related illnesses has resulted in hundreds of visits to hospitals and at least seven deaths in the United States. Investigators have yet to determine exactly what about vaping is causing these life-threatening symptoms, but there's a good chance that industry changes, including ...

Medmen Enterprises Inc (OTCMKTS:MMNFF) just announced that the waiting period under the Hart-   Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to its proposed   acquisition of PharmaCann, LLC. According to the release, the expiration of...